News >

Gomella Discusses Apalutamide Approval and Other Progress in Prostate Cancer

Angelica Welch
Published: Friday, Feb 23, 2018

Dr. Leonard G. Gomella

Leonard G. Gomella, MD
The recent FDA approval of apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC) is a tremendous therapeutic breakthrough, according to Leonard Gomella, MD.

Apalutamide was approved based on the phase III SPARTAN trial, in which the androgen receptor (AR) inhibitor reduced the risk of metastasis or death by 72% in patients with nonmetastatic CRPC.1 The median metastasis-free survival was 40.5 months in the apalutamide arm versus 16.2 months in the placebo arm (HR, 0.28; 95% CI, 0.23-0.35; P <.0001).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x